- Home
- ENLT vs SLNO Comparison
ENLT vs SLNO Comparison
Compare ENLT & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENLT | SLNO |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 2.5B |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ENLT | SLNO |
|---|---|---|
| Price | $43.61 | $49.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $37.50 | ★ $110.90 |
| AVG Volume (30 Days) | 30.0K | ★ 1.6M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.72 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $457,756,000.00 | $98,675,000.00 |
| Revenue This Year | $355.90 | N/A |
| Revenue Next Year | $42.83 | $155.86 |
| P/E Ratio | $43.59 | ★ N/A |
| Revenue Growth | ★ 27.72 | N/A |
| 52 Week Low | $14.01 | $41.50 |
| 52 Week High | $42.38 | $90.32 |
Technical Indicators
Market Signals| Indicator | ENLT | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 67.95 | 46.09 |
| Support Level | $38.48 | $48.60 |
| Resistance Level | $40.03 | $50.95 |
| Average True Range (ATR) | 1.14 | 2.64 |
| MACD | 0.09 | 0.23 |
| Stochastic Oscillator | 91.24 | 27.59 |
Price Performance
Historical ComparisonAbout ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.